1-3 of 3
Esther CW Breij
Close
Sort by
Journal Articles

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD, Maarten L Janmaat, PhD, Peter Boross, PhD, Jeroen van den Brakel, Wessel ten Hagen, Sanne van Dooremalen, Sieto Bosgra, PhD, Bart ECG De Goeij, PhD, Grietje Andringa, Laurens Kil, PhD, A Kate Sasser, PhD, Tahamtan Ahmadi, MD PhD, David Satijn, PhD, Esther CW Breij, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-140313
Published: 2020
Journal Articles

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Hilma J Van Der Horst, MSc, A. Vera de Jonge, Ida H Hiemstra, PhD, Anne T Gelderloos, MSc, Daniella RAI Berry, Nathalie J Hijmering, Daphne de Jong, Prof Dr, Martine E.D. Chamuleau, Sonja Zweegman, MD PhD, Esther CW Breij, DPhil, Margaretha GM Roemer, PhD, Tuna Mutis
Journal: Blood
Blood (2019) 134 (Supplement_1): 4066.
https://doi.org/10.1182/blood-2019-125765
Published: 2019
Journal Articles

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Hilma J van der Horst, Marije B Overdijk, Esther CW Breij, Martine Chamuleau, MD PhD, Henk M Lokhorst, Tuna Mutis, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1835.
https://doi.org/10.1182/blood.V130.Suppl_1.1835.1835
Published: 2017